(Q33817568)

29 July 2017

Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design (English)

1 reference

focal segmental glomerulosclerosis

29 July 2017

phase II clinical trial

0 references

1 reference

5

Jennifer Gassman

1 reference

29 July 2017

Maury Pinsk

9

0 references

Debbie S Gipson

object named as

Debbie Gipson

3

0 references

Howard Trachtman

object named as

Howard Trachtman

1

0 references

Virginia J Savin

7

object named as

Virginia Savin

1 reference

29 July 2017

Suzanne Vento

2

1 reference

29 July 2017

Larysa Wickman

4

1 reference

29 July 2017

Melanie Joy

6

1 reference

29 July 2017

Michael Somers

8

1 reference

29 July 2017

Tom Greene

10

1 reference

29 July 2017

10 February 2011

1 reference

29 July 2017

1 reference

29 July 2017

12

1 reference

29 July 2017

8

1 reference

Creative Commons Attribution 2.0 Generic

29 July 2017

start time

10 February 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2369-12-8

0 references

cites work

Oral hypoglycaemics - a review of the evidence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

The differential effect of race among pediatric kidney transplant recipients with focal segmental glomerulosclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Regulation of proliferation, survival and apoptosis by members of the TNF superfamily

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Broadening the spectrum of diseases related to podocin mutations

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Other immunosuppressive agents for focal segmental glomerulosclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Primum non nocere: Should adults with idiopathic FSGS receive steroids?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

The genetic basis of FSGS and steroid-resistant nephrosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Focal segmental glomerulosclerosis: pathogenesis and treatment

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

American Cancer Society guidelines for the early detection of cancer, 2003.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Renoprotection: one or many therapies?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Management of focal segmental glomerulosclerosis: evidence-based recommendations.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

4 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-12-8

Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-12-8

Effect of lipid reduction on the progression of renal disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-12-8

The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-12-8

Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-12-8

FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-12-8

Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-12-8

NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF-alpha

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045306

Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: either or both for primary renal disease

30 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-12-8

Serial Estimates of Serum Permeability Activity and Clinical Correlates in Patients with Native Kidney Focal Segmental Glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-12-8

Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts

21 January 2018

1 reference

12 December 2020

Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study

1 reference

12 December 2020

Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis

1 reference

12 December 2020

Long-term therapy with enalapril in patients with nephrotic-range proteinuria

1 reference

12 December 2020

ACE-inhibitors: panacea for progressive renal disease

1 reference

12 December 2020

TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide

1 reference

12 December 2020

Long-term outcome in children and adults with classic focal segmental glomerulosclerosis

1 reference

12 December 2020

Enalapril: antiproteinuric effect in children with nephrotic syndrome

1 reference

12 December 2020

ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis

1 reference

12 December 2020

Treatment of primary focal segmental glomerulosclerosis

1 reference

12 December 2020

Retarding the progression of renal disease

1 reference

12 December 2020

Randomized phase II clinical trials

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2369-12-8

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference